Kymera Therapeutics, Inc. KYMR
We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients' lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Our approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner.
We are a leader in targeted protein degradation (TPD), a next-generation small molecule therapeutic modality that engages the body's natural cellular recycling system to selectively eliminate disease-causing proteins. Our objective is to develop molecules that are both potent and highly selective, creating the unique potential to address diseases that are poorly served by current treatment options. To date, we have progressed multiple programs into clinical development and expect to advance at least one new molecular entity into clinical testing annually. We intend to leverage our drug development expertise to become a fully integrated biopharmaceutical company with an industry-leading pipeline of novel medicines.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $72.8M | $34.0M | $2.9M | — |
| Cost of revenue | $39.2M | $47.1M | $78.6M | $46.8M | — | — | — | — |
| Gross profit | $0 | $0 | $0 | $0 | — | — | — | — |
| R&D | $316.6M | $240.2M | $189.1M | $164.2M | $137.0M | $62.1M | $37.2M | — |
| SG&A | $68.2M | $63.5M | $55.0M | $43.8M | $36.3M | $18.2M | $8.0M | — |
| Total operating expenses | $388.6M | $308.7M | $244.1M | $208.1M | $173.4M | $80.3M | $45.1M | — |
| Operating income | -$349.4M | -$261.6M | -$165.5M | -$161.3M | -$100.5M | -$46.3M | -$42.2M | — |
| Pre-tax income | -$311.4M | — | — | $154.8M | $100.2M | -$45.6M | -$41.2M | — |
| Income tax | $0 | — | — | $0 | $0 | $0 | $0 | — |
| Net income | $311.4M | $223.9M | $147.0M | $154.8M | $100.2M | -$45.6M | -$41.2M | — |
| EPS, basic | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 | — | — |
| EPS, diluted | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 | -24.28 | — |
| Shares, diluted (wtd. avg.) | 84.5M | 75.0M | 58.4M | 53.9M | 48.0M | 17.3M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $357.0M | $120.3M | $110.0M | $68.4M | $48.0M | $31.0M | $76.0M | — |
| Short-term investments | $491.3M | $368.5M | $264.9M | $338.8M | $394.4M | $265.2M | $15.9M | — |
| Receivables | — | $0 | $15.0M | $0 | — | — | — | — |
| Total current assets | $871.2M | $510.3M | $405.3M | $419.4M | $451.3M | $302.3M | $92.8M | — |
| Property, plant and equipment | $43.2M | $50.5M | $48.1M | $13.3M | $11.9M | $10.8M | $3.8M | — |
| Total assets | $1.74B | $978.0M | $575.8M | $603.1M | $605.9M | $487.2M | $116.7M | — |
| Accounts payable | $4.0M | $6.0M | $7.1M | $4.3M | $4.0M | $4.4M | $3.3M | — |
| Total current liabilities | $83.2M | $67.8M | $85.7M | $71.3M | $92.5M | $110.6M | $34.6M | — |
| Total liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M | $203.3M | $82.0M | — |
| Retained earnings | -$1.07B | -$754.6M | -$530.8M | -$383.8M | -$229.0M | -$128.8M | -$76.5M | — |
| Total equity | $1.58B | $835.6M | $395.0M | $490.2M | $459.6M | $283.9M | -$74.4M | -$34.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$232.9M | -$194.5M | -$102.8M | -$153.1M | -$128.9M | $88.1M | $17.9M | — |
| Depreciation and amortisation | $8.3M | $7.4M | $3.6M | $3.0M | $2.4M | $1.8M | $825.0K | — |
| Stock-based compensation | $59.9M | $55.0M | $43.1M | $35.5M | $25.0M | $5.2M | $1.2M | — |
| Capital expenditure | $1.4M | $12.8M | $34.5M | $2.8M | $1.6M | $9.1M | $532.0K | — |
| Investing cash flow | -$521.1M | -$404.1M | $139.9M | $20.5M | -$99.8M | -$422.6M | -$16.5M | — |
| Financing cash flow | $990.7M | $608.9M | $4.2M | $153.0M | $250.3M | $289.3M | $34.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-191495.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Gross profit | — | — | — | — | $0 | $0 | $0 | $0 |
| Net income | — | -$41.2M | -$45.6M | $100.2M | $154.8M | $147.0M | $223.9M | $311.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Results announced Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |